MOVEMENT DISORDERS

The drug is currently approved for the treatment of Parkinson disease-related psychosis, and is also being explored in schizophrenia and major depressive disorder.
Neurology News Network for the week ending September 7, 2019.

SAP Partner Banner

About NeurologyLive's Movement Disorders Clinical Focus page:

The NeurologyLive Movement Disorder Clinical Focus center provides a source of up-to-date clinical information, with articles covering updates from the robust pipeline of novel therapies, and the newest data from all phases of clinical trials and studies in the space. It also serves as a hub of information and news from the upcoming and ongoing conferences and annual meetings hosted by neurological societies and associations on the latest advances in Parkinson disease, Tardive dyskinesia, Huntington disease, and more. 
 
This resource includes a wealth of interviews with movement disorder specialists, and moderated Peer Exchange discussions about the best practices and key methods for treating complex cases, utilizing the newest therapies, examining the issues and challenges of treatment options, and much more.